CR11295A - 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos - Google Patents

2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos

Info

Publication number
CR11295A
CR11295A CR11295A CR11295A CR11295A CR 11295 A CR11295 A CR 11295A CR 11295 A CR11295 A CR 11295A CR 11295 A CR11295 A CR 11295A CR 11295 A CR11295 A CR 11295A
Authority
CR
Costa Rica
Prior art keywords
anilinopurin
onas
ttk
treatment
proliferative disorders
Prior art date
Application number
CR11295A
Other languages
English (en)
Inventor
David Michael Andrews
Clifford David Jones
Ianin Simpson
Richard Andrew Ward
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CR11295A publication Critical patent/CR11295A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invencion se refiere a compuestos quimicos de la formula (I) o una sal farmaceutica aceptable de estos, que poseen actividad inhibitoria frente a la cinasa del punto de control del huso.
CR11295A 2007-08-23 2010-02-23 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos CR11295A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95750807P 2007-08-23 2007-08-23

Publications (1)

Publication Number Publication Date
CR11295A true CR11295A (es) 2010-05-28

Family

ID=39951669

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11295A CR11295A (es) 2007-08-23 2010-02-23 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos

Country Status (19)

Country Link
US (1) US20110118238A1 (es)
EP (1) EP2212326A1 (es)
JP (1) JP2010536841A (es)
KR (1) KR20100057650A (es)
CN (1) CN103298814A (es)
AU (1) AU2008290330A1 (es)
BR (1) BRPI0815709A2 (es)
CA (1) CA2696200A1 (es)
CO (1) CO6260060A2 (es)
CR (1) CR11295A (es)
DO (1) DOP2010000064A (es)
EA (1) EA201000341A1 (es)
EC (1) ECSP10010034A (es)
MX (1) MX2010002115A (es)
NI (1) NI201000032A (es)
NZ (1) NZ584138A (es)
SV (1) SV2010003491A (es)
WO (1) WO2009024824A1 (es)
ZA (1) ZA201001193B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080119496A1 (en) * 2006-11-16 2008-05-22 Pharmacopeia Drug Discovery, Inc. 7-Substituted Purine Derivatives for Immunosuppression
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
EP2343297A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
EP2343294A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
EP2343295A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridine derivates
FR2955109B1 (fr) 2010-01-08 2012-09-07 Sanofi Aventis Derives de 5-oxo-5,8-dihydro-pyrido[2, 3-d]pyrimidine, leur preparation et leur application en therapeutique
UY33452A (es) 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas
UY33539A (es) * 2010-08-02 2012-02-29 Astrazeneca Ab Compuestos químicos alk
EP2651948A1 (en) * 2010-12-17 2013-10-23 Bayer Intellectual Property GmbH Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment hyperproliferative disorders
EP2651947B1 (en) * 2010-12-17 2014-12-10 Bayer Intellectual Property GmbH 6-thio-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
CN103429592A (zh) * 2010-12-17 2013-12-04 拜耳知识产权有限责任公司 作为mps-1和tkk抑制剂用于治疗过度增殖性病症的6-取代的咪唑并吡嗪
JP5824065B2 (ja) * 2010-12-17 2015-11-25 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 過剰増殖性障害の治療におけるｍｐｓ−１およびｔｋｋ阻害剤として使用するための６置換イミダゾピラジン
CN103370322B (zh) * 2010-12-17 2016-02-10 拜耳知识产权有限责任公司 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的2-取代的咪唑并吡嗪
EP2651950A1 (en) * 2010-12-17 2013-10-23 Bayer Intellectual Property GmbH 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
PL2699575T3 (pl) 2011-04-21 2015-08-31 Bayer Ip Gmbh Triazolopirydyny
WO2012160029A1 (en) 2011-05-23 2012-11-29 Bayer Intellectual Property Gmbh Substituted triazolopyridines
UA112096C2 (uk) 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
JP6166289B2 (ja) 2012-03-14 2017-07-19 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換イミダゾピリダジン
NZ703020A (en) 2012-07-10 2017-08-25 Bayer Pharma AG Method for preparing substituted triazolopyridines
WO2014020043A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
WO2014195274A1 (en) * 2013-06-07 2014-12-11 Bayer Pharma Aktiengesellschaft Substituted triazolopyridines
PT3008062T (pt) 2013-06-11 2017-06-07 Bayer Pharma AG Derivados de profármaco de triazolopiridinas substituídas
GB201403536D0 (en) * 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
CN107567503B (zh) 2015-04-17 2022-03-22 荷兰转化研究中心有限责任公司 用于ttk抑制剂化疗的预后生物标记
PE20191474A1 (es) 2016-12-20 2019-10-16 Astrazeneca Ab Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer
US11052091B2 (en) 2016-12-21 2021-07-06 Ono Pharmaceutical Co., Ltd. BRK inhibitory compound
TWI820146B (zh) * 2018-06-15 2023-11-01 瑞典商阿斯特捷利康公司 嘌呤酮化合物及其在治療癌症中之用途
WO2020185044A1 (ko) * 2019-03-13 2020-09-17 주식회사 보로노이 헤테로아릴 유도체 및 이를 유효성분으로 포함하는 약학적 조성물
CN114315834B (zh) * 2020-04-17 2024-01-05 成都百裕制药股份有限公司 咪唑啉酮衍生物及其在医药上的应用
KR102409595B1 (ko) * 2020-06-29 2022-06-17 한국과학기술연구원 단백질 카이네이즈 csf-1r 억제제로서의 신규 퓨리논 유도체
CZ309356B6 (cs) * 2020-09-15 2022-09-28 Ústav experimentální botaniky AV ČR, v. v. i Substituované purinové sloučeniny jako inhibitory proteinkináz, jejich použití jako léčiva a farmaceutické přípravky obsahující tyto deriváty
TW202241901A (zh) * 2020-12-21 2022-11-01 大陸商江蘇恆瑞醫藥股份有限公司 嘌呤酮衍生物、其製備方法及其在醫藥上的應用
WO2022199547A1 (zh) * 2021-03-22 2022-09-29 成都赜灵生物医药科技有限公司 一种7,9-二氢嘌呤衍生物及其制药用途
TWI823531B (zh) * 2021-08-23 2023-11-21 大陸商成都百裕製藥股份有限公司 咪唑啉酮衍生物或者其立體異構體的製備方法及其中間體
MX2024003693A (es) * 2021-09-23 2024-04-09 Chengdu Baiyu Pharmaceutical Co Ltd Forma cristalina del derivado de imidazolinona.
WO2024012516A1 (zh) * 2022-07-13 2024-01-18 成都百裕制药股份有限公司 咪唑啉酮衍生物在联合放疗治疗肿瘤中的应用
CN120129526A (zh) * 2022-07-20 2025-06-10 成都百裕制药股份有限公司 咪唑啉酮衍生物联合多柔比星在治疗肿瘤中的应用
JP2025539576A (ja) * 2022-12-13 2025-12-05 カンバイダ （スーチュアン） バイオテクノロジー シーオー．， エルティーディー． イミダゾリノン化合物の医薬製剤、その調製方法及びその使用
TW202513059A (zh) * 2023-09-21 2025-04-01 大陸商成都百裕製藥股份有限公司 咪唑啉酮衍生物在製備用於聯合放療治療腫瘤的藥物中的應用及治療方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2411975T3 (es) * 2005-01-14 2013-07-09 Janssen Pharmaceutica Nv Pirimidinas heterocíclicas anilladas de 5 miembros como inhibidores de cinasas
WO2006091737A1 (en) * 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
JO3235B1 (ar) * 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها

Also Published As

Publication number Publication date
CO6260060A2 (es) 2011-03-22
JP2010536841A (ja) 2010-12-02
ECSP10010034A (es) 2010-04-30
US20110118238A1 (en) 2011-05-19
NI201000032A (es) 2010-12-07
NZ584138A (en) 2011-10-28
BRPI0815709A2 (pt) 2017-06-13
ZA201001193B (en) 2010-10-27
AU2008290330A1 (en) 2009-02-26
MX2010002115A (es) 2010-06-01
CN103298814A (zh) 2013-09-11
WO2009024824A1 (en) 2009-02-26
EA201000341A1 (ru) 2010-10-29
EP2212326A1 (en) 2010-08-04
CA2696200A1 (en) 2009-02-26
DOP2010000064A (es) 2010-03-31
SV2010003491A (es) 2010-07-06
KR20100057650A (ko) 2010-05-31

Similar Documents

Publication Publication Date Title
CR11295A (es) 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos
NI201600058A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4
BR112017019286A2 (pt) composto de fórmula (i) ou um sal farmaceuticamente aceitável deste
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
BR112018074621A2 (pt) derivados de pirazolopirimidina como inibidores de quinase
MX373307B (es) Compuestos de biaril-amida como inhibidores de cinasa.
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
EA200900983A1 (ru) Соединения и композиции в качестве ингибиторов киназы
MX2018000512A (es) Compuestos de indazaol y azaindazol como inhibidores de la cinasa 4 asociada al receptor de interlucina 1 (irak-4).
NI201100166A (es) Derivados de benzofuranilo utilizados como inhibidores de glucoquinasa
PH12017500416A1 (en) Compounds and compositions as raf kinase inhibitors
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
BR112018008966A2 (pt) compostos inibidores de jak quinase para o tratamento de doença respiratória
DOP2015000158A (es) Inhibidores de prmt5 y sus usos
EA201170872A1 (ru) Ингибиторы протеинкиназы
SV2011004061A (es) Aril-piridinas como inhibidores de sintasa de aldosterona
CR20140223A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
BR112016024533A2 (pt) derivados de amino pirazina como inibidores de fosfatidilinositol 3-cinase
CL2015002608A1 (es) Compuesto de amino-pirazol y usos medicinales relacionados.
BR112017016817A2 (pt) derivados heterocíclicos formilados como inibidores de fgfr4
BR112012029994A2 (pt) composto heterocíclicos como inibidores de janus quinase
BR112016024484A2 (pt) derivados de aminopiridina como inibidores de fosfatidilinositol 3-quinase
BR112016023967A2 (pt) derivados de pirazina como inibidores de fosfatidilinositol 3-cinase
MX2019010595A (es) Derivados de pirrolotriazina como inhibidores de cinasas.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)